Insider Trading Alert - JLL, SF And OPK Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, March 10, 2014, 109 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $50.96 to $374,999,999.94.

Highlighted Stocks Traded by Insiders:

Jones Lang LaSalle (JLL) - FREE Research Report

Hughes Alastair who is CEO of Europe at Jones Lang LaSalle sold 12,000 shares at $122.63 on March 10, 2014. Following this transaction, the CEO of Europe owned 28,879 shares meaning that the stake was reduced by 29.35% with the 12,000-share transaction.

The shares most recently traded at $122.69, up $0.06, or 0.05% since the insider transaction. Historical insider transactions for Jones Lang LaSalle go as follows:

  • 4-Week # shares sold: 4,500
  • 12-Week # shares sold: 10,500
  • 24-Week # shares sold: 23,500

The average volume for Jones Lang LaSalle has been 377,600 shares per day over the past 30 days. Jones Lang LaSalle has a market cap of $5.5 billion and is part of the financial sector and real estate industry. Shares are up 21.03% year-to-date as of the close of trading on Friday.

Jones Lang LaSalle Incorporated, a financial and professional services firm, provides integrated real estate and investment management services to owner, occupier, investor, developer clients worldwide. The stock currently has a dividend yield of 0.36%. The company has a P/E ratio of 20.7. Currently there are 2 analysts that rate Jones Lang LaSalle a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on JLL - FREE

TheStreet Quant Ratings rates Jones Lang LaSalle as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, impressive record of earnings per share growth, compelling growth in net income and attractive valuation levels. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full Jones Lang LaSalle Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Stifel Financial (SF) - FREE Research Report

Himelfarb Richard J who is Director at Stifel Financial sold 25,000 shares at $48.00 on March 10, 2014. Following this transaction, the Director owned 271,819 shares meaning that the stake was reduced by 8.42% with the 25,000-share transaction.

The shares most recently traded at $48.26, up $0.26, or 0.54% since the insider transaction. Historical insider transactions for Stifel Financial go as follows:

  • 4-Week # shares sold: 11,000
  • 12-Week # shares sold: 11,000
  • 24-Week # shares sold: 241,665

The average volume for Stifel Financial has been 378,100 shares per day over the past 30 days. Stifel Financial has a market cap of $3.1 billion and is part of the financial sector and financial services industry. Shares are up 0.38% year-to-date as of the close of trading on Friday.

Stifel Financial Corp., a financial holding company, provides retail and institutional brokerage, and investment banking services in the United States, Canada, and Europe. The company has a P/E ratio of 20.3. Currently there is 1 analyst that rates Stifel Financial a buy, 1 analyst rates it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SF - FREE

TheStreet Quant Ratings rates Stifel Financial as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, compelling growth in net income and solid stock price performance. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Stifel Financial Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Opko Health (OPK) - FREE Research Report

Frost Phillip Md Et Al who is CEO & Chairman at Opko Health bought 10,000 shares at $9.20 on March 10, 2014. Following this transaction, the CEO & Chairman owned 139.5 million shares meaning that the stake was reduced by 0.01% with the 10,000-share transaction.

The shares most recently traded at $9.24, up $0.04, or 0.43% since the insider transaction. Historical insider transactions for Opko Health go as follows:

  • 4-Week # shares bought: 10,000
  • 4-Week # shares sold: 46,730
  • 12-Week # shares bought: 30,000
  • 12-Week # shares sold: 46,730
  • 24-Week # shares bought: 30,000
  • 24-Week # shares sold: 46,730

The average volume for Opko Health has been 4.1 million shares per day over the past 30 days. Opko Health has a market cap of $3.7 billion and is part of the health care sector and health services industry. Shares are up 6.52% year-to-date as of the close of trading on Friday.

Opko Health, Inc., a pharmaceutical and diagnostics company, engages in the discovery, development, and commercialization of novel and proprietary technologies. It operates in two segments, Pharmaceuticals and Diagnostics. Currently there are 3 analysts that rate Opko Health a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on OPK - FREE

TheStreet Quant Ratings rates Opko Health as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and weak operating cash flow. Get the full Opko Health Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Data for this article provided by Zacks Investment Research

null

More from Markets

Jim Cramer: Centene Is in All the Big Medicare Markets

Jim Cramer: Centene Is in All the Big Medicare Markets

Jim Cramer on the Markets: I Struggle With How Negative Things Are

Jim Cramer on the Markets: I Struggle With How Negative Things Are

Video: Jim Cramer on Tariff Worries, Oil, Alphabet and Centene

Video: Jim Cramer on Tariff Worries, Oil, Alphabet and Centene

Emerging Markets Get Pounded by Trade War Concerns

Emerging Markets Get Pounded by Trade War Concerns

Dow Tumbles, Stocks Slide on Renewed Trade War Concerns

Dow Tumbles, Stocks Slide on Renewed Trade War Concerns